FHD-286
FHD-286-C-001
Phase 1 small_molecule terminated
Quick answer
FHD-286 for Metastatic Uveal Melanoma is a Phase 1 program (small_molecule) at Foghorn Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Foghorn Therapeutics
- Indication
- Metastatic Uveal Melanoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated